Foxp3, a member of the forkhead transcription factor family, is a master gene that controls the development and function of CD4 
Introduction
Leukemia is a cancer of white blood cells disseminated by blood circulation. T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of ALL. 1 The development of leukemia is a complex, multistep process that involves not only oncogenes or tumor-suppressor gene mutation of cells but also cross talking between leukemia and the environment. 2, 3 Though a number of leukemia cell lines of T-cell origin have been established, [4] [5] [6] [7] maintaining primary culture of leukemia cells remains difficult if lacking certain in vivo factors. 8 Aside from offering something necessary from the surrounding environment created by the neoplasm for growth, immunosurveillance may also help eliminate potential cancer cells. 9 To survive, tumor cells escape from immunosurveillance through a mechanism of immunoediting that enables tumor cell to display either reduced immunogenicity or increased ability to inhibit protective antitumor immune response. 10 Cross talking between cancer immunosurveillance and immunoediting involves many factors related to active tumor progression, such as NKG2D, IFN-a and b, and IL-23. 11 This implies that the in vivo environment 'educates' tumor cells by immunoediting to survive. It is a novel strategy to suppress tumor expansion by manipulating the tumor microenvironment.
The homeostasis of the immune system is maintained by an elaborate tolerance mechanism not only to discriminate between self and nonself but also to regulate overreaction of the immune function. 12, 13 One of the most important tolerance mechanisms is the CD4 + CD25 + regulatory T (Treg) cells, which behave in a dominant extrinsic manner. 14, 15 Tregs share most features with conventional T cells, such as CD4, CD5, CD25, CD28, CTLA-4, GITR, CD62L, LAG-3 (CD223) and CCR4. Thus, there is no definitive marker for Treg cells so far. However, the forkhead transcription regulatory factor, Foxp3, is a major factor in Treg function and one of the most important markers of CD4 + CD25
+ Treg cells. [16] [17] [18] CD4 + CD25 + Foxp3 + Treg cells have an important role in the mechanism of tumor immunoediting to escape from the immune system. 10 Many studies reported that Treg cells are increased in the blood and tumor microenvironment in different tumors, such as ovarian carcinoma and pancreatic, breast or pancreatic ductal adenocarcinoma. [19] [20] [21] [22] Foxp3 expression in pancreatic carcinoma cells completely inhibit T-cell proliferation, an effect that is partially abrogated by the specific inhibition of Foxp3 expression. 23 It may be a selective maker for a subset of T-cell leukemia for its 68% expression in adult T-cell leukemia/lymphoma (ATLL). 24 High but not low expression by leukemia cells isolated from patients with ATLL show suppressive activity similar to Treg cells through cell-cell contact-dependent mechanisms. 25 ATLL patients are highly immunocompromised because ATLL cells function as Treg cells in an autologous setting.
26
Foxp3 directly controls Treg cell function by interacting with transcription factor acute myeloid leukemia1 (AML1) and Runt-related transcription factor 1 (Runx1) to suppress IL-2 and IFN-g production, upregulate Treg cell-associated molecules and exert suppressive function. 27 Foxp3 + Treg cells not only inhibit T-cell activation but also induce cytokine deprivation-mediated apoptosis of effector T cells. 28 However, vaccination against Foxp3 enhances tumor immunity. + leukemia cell, were generated from irradiated Balb/c mice. 30 
Results

RL#1 leukemia cells express the characteristics of Treg cells
Compared to Treg isolated from CD4 + CD25 + (94. 08%) of naïve Balb/c mice, flow cytometric analysis showed that tumor cells had high levels of CD4 and CD25 at the frequencies of 95.51% (Figure 1a ). Similar to Treg cells, RL#1 cells also expressed Foxp3 up to 88% by intracellular staining with specific antibodies (Figure 1a) . However, the mean fluorescence intensity of RL#1 was only half when compared to CD4 + CD25 + cells ( Figure  1b ). Q-PCR was done to determine differences in Foxp3 expression levels between Treg cells and RL#1 cells. In terms of Foxp3 expression related to the endogenous gene HPRT, CD4 + CD25 + Treg cells isolated from naïve 
Selection of shRNAs sequence for targeted degradation of Foxp3 mRNA
To easily determine the knockdown efficiency of siRNA for murine Foxp3 mRNA (mFoxp3), we constructed mFoxp3 cDNA into the pIRES-hrGFP-1a vector to monitor its expression at the single-cell level. pIRESmFoxp3 contained a dicistronic expression cassette that allowed the expression of Foxp3 and hrGFP on the same transcript. Once the siRNA knocked down the mFoxp3 mRNA, the mRNA of hrGFP was degraded due to the instability of the mRNA structure. The three double strain siRNAs and control siRNA were co-transfected with indicator plasmid, pIRES-GFP and pIRES-GFPmFoxp3, into 293 cells, respectively.
When pIRES-GFP-mFoxp3 transfected cells were treated with siFoxp3-1, siFoxp3-2 or siFoxp3-3, the GFP expression became lower compared to the control siRNA as analyzed under a fluorescent microscope ( Figure 2) . Furthermore, the three shRNAs did not show any suppressive effect on GFP expression on pIRES-GFP transfected cells. It excluded the nonspecific targeting effect on other mRNA expression. Among the three sequences, siFoxp3-1 showed better suppressive effect to GFP mRNA than the other two and it was chosen for the subsequent experiments.
Foxp3 gene silencing and production of processed shRNAs in RL#1 leukemia cells lines
The study investigated whether the lentiviral vectorexpressed specific shRNAs for Foxp3 (Lenti-Foxp3-siRNA) could silence Foxp3 expression in RL#1 cells. A 96% infection rate was attained and analyzed by flow cytometry (Figure 3a To determine whether tumor infected with Lenti-Foxp3-siRNA changed in proliferation rate, we conducted proliferation assay. There were no significant differences between RL#1 infected with Lenti-Foxp3-siRNA and those with Lenti-mock (Figure 4b ). To determine the therapeutic effects of Lenti-Foxp3-siRNA in the leukemia animal model, we injected Lenti-Foxp3-siRNA or Lenti-mock intratumor into mice at day 9 after tumor transplanted until day 26 (Figure 7a ). Lenti-Foxp3-siRNA suppressed tumor growth compared to tumor mice treated with Lenti-mock or phosphatebuffered saline (Figure 7b ).
Discussion
Several studies have focused on evaluating the therapeutic effects of gene silencing in a variety of diseases, especially while antisense technology shows highly + with high expression of Foxp3 (Figure 1 ). Foxp3, the most important characteristic of natural Treg cells, is the disease-causative gene in scurfy mice, which spontaneously develop severe autoimmunity. 32 Interestingly, RL#1 leukemia express Foxp3 after in vivo passage and it has features of CD4 + CD25 + Treg cells. This reflects the possibility that the pathology of leukemia arise from Treg or leukemia cells exacerbating the suppressive function of immune function. Indeed, Foxp3 is not only a selective marker for a subset of ATLL but is also a possible pathogenic pathway of leukemia. [24] [25] [26] 33 Foxp3 directly controls Treg cell function by interacting with the transcription factor AML1 and the Runx1 to suppress IL-2 and IFN-g production, upregulate Treg cell-associated molecules and exert suppressive activity. 27, 34, 35 The new antisense strategy, RNA interference (RNAi), is one of the most potent. Delivered exogenously or expressed endogenously from RNA polymerase II or III promoter, it leads to the specific downregulation of target mRNA. 37 Therefore, this study investigated the therapeutic role of RNAi of Foxp3 in a murine model of leukemia. To overcome poor transfection efficiency, the lentiviral vector is used as the delivery tool in shRNAs for gene silencing studies. [38] [39] [40] In this study, Foxp3 shRNAs has been constructed and delivered by lentiviral vectors (Lenti-Foxp3-siRNA) to investigate their therapeutic effects in leukemia. RL#1 decreases Foxp3 expression after infection with lenti-Foxp3-siRNA by Q-PCR analysis of mRNA expression levels ( Figure 3) . When Foxp3 gene expression is suppressed, the suppressive activity of tumor cells also decreases (Figure 4b ).
In addition, mice transplanted with the Foxp3 gene silenced tumor cells modified with Lenti-Foxp3-siRNA show lower tumor growth rate (Figure 5a ) and more prolonged survival time compared to mock control (Figure 5b ). Tumor cells infected with Lenti-Foxp3-siRNA or Lenti-mock show similar tumor growth curve or survival time in immunodeficient mice, such as NOD-SCID mice (Figure 6 ). This represents the critical role of Foxp3 in leukemia tumorigenesis. Intratumor injection of Lenti-Foxp3-siRNA into tumor-transplanted mice suppresses tumor growth and shows the therapeutic effects of Lenti-Foxp3-siRNA (Figure 7) .
The relationships among Foxp3, IL-10 and TGF-b are still unclear. Mice with a 'dual-reporter' system of genes encoding IL-10 and Foxp3 to track Treg subsets by a conditional induction of these genes show that Foxp3 + and Foxp3
À precursor cells give rise to peripheral IL-10-expressing Treg cells by a mechanism dependent on TGF-b and independent of IL-10. 41 The secretion of IL-10 and TGF-b is mildly upregulated by the specific knockdown of Foxp3 (data not shown). Whether TGF-b is necessary for keeping Foxp3 expression remains uncertain because after in vitro culture for several generations, Foxp3 expression decreasing tumor cells still constitutively produce TGF-b.
Previous studies show that lentiviral vectors expressing shRNAs against polymerase III promoters induce side effects by expressing interferon-stimulated genes. [38] [39] [40] This may be harmless in this experiment because the induction of interferon-stimulated genes is helpful in some ways regarding target therapy of tumor. Moreover, some studies have shown that siRNAs induce gene expression. 42, 43 Whether this phenomenon can happen warrants more investigation. Further modification of lentiviral vectors is possible to prevent immune response in patients infected with HIV vector. In the future, nanoparticles carrying RNAi should be considered for human clinical application.
Targeting genetic molecules involved in the disease process has become a major objective in modern molecular therapeutic approach. Targeting mRNA rather than the protein itself is a more efficient approach to block protein function based on the idea that each mRNA molecule produces multiple copies of a protein (approximately 5000 copies). This study shows that the Foxp3 shRNA lentivirus vector can be a potent inhibitor of tumor growth of Treg-like leukemia, even though the specificity, safety and delivery tool of RNAi need further studies for in vivo treatment in the future. This study suggests that Foxp3 directly contributes to the tumorigenesis of leukemia and may be one of the most important pathologic mechanisms of Treg-like leukemia. It may be another future consideration for leukemia immunotherapy.
Materials and methods
Tumor cells and mice
RL#1 is a cell line derived from radiation-induced T-cell leukemia in Balb/c mice. 30 The cells were maintained in Balb/c mice by in vivo passage. Briefly, RL#1 cells (10 6 cells per mouse) were injected intraperitoneally into Balb/c mice. Cells were harvested 10-14 days after and stored in liquid nitrogen until the next experiment. For each experiment, we thawed and grew the cells in RPMI-1640 medium supplemented with 10% fetal calf serum (Gibco Laboratories, Grand Island, NY, USA). Male Balb/c mice aged 6-10 weeks were purchased from the Animal Center of the College of Medicine of the National Taiwan University Hospital (Taipei, Taiwan). The Animal Research Committee of National Taiwan University approved all animal experiment protocols. To determine the knockdown efficiency of shRNA for Foxp3 mRNA, we inserted murine Foxp3 cDNA at the EcoRI restriction site of the plasmid vector pIREShrGFP-1a (humanized recombinant green fluorescence protein) (Stratagene, Foster city, TX, USA). Three predesigned shRNA-targeted sequences, siFoxp3-1, siFoxp3-2 and siFoxp3-3, specific for mFoxp3 were synthesized (Ambion, Austin, TX, USA). To determine the specificity of targeting degradation of Foxp3 mRNA expression, we co-transfected plasmids (1 mg) and shRNA (500 pmol) into 293-cell line using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Briefly, 293 cells were seeded into 24-well culture plate until 80% confluence at the time of transfection. After washing with serum-free medium, we added the prepared mixture that combined proper volume of Lipofectamine and indicator vectors plus siRNAs into the well. After 24 h of transfection, we observed the GFP expression of 293 cells under fluorescence microscope.
Construction and cloning of shRNAs into lentiviral vectors
Target sequences selected were sense, GGACACUCAAUGAAAUCUAtt, and antisense, UAGAUUUCAUUGAGUGUCCtc, for Foxp3 RNAi. The shRNAs were synthesized by PCR-derived shRNA expression cassettes according to the manufacturer's procedure (Ambion). shRNAs were cloned into pTY linkers (lentiviral vectors). The lentiviral vectors used in the experiment were third-generation, self-inactivated vectors. 44 shRNA lentiviral vector production was by calcium phosphate-mediated transient transfection of HEK-293T cells. Briefly, HEK-293T cells were co-transfected with appropriate amounts of vector plasmids, including helper construct, envelope plasmid, tat plasmid and pTYlinker containing shRNAs. The viruses were collected and concentrated 100-fold by ultracentrifugation. The concentrated virus stocks were titrated on HEK-293T cells based on GFP expression. The concentration of different viral vectors used for transduction of RL#1 cells was 1.4 multiplicity of infection (virus titer 2.8 Â 10 5 IFU).
Real-time PCR
Total RNA was isolated by TRIzol reagent (Invitrogen) and converted to cDNA by the SuperScript II First-Strand Synthesis for RT-PCR kit (Invitrogen) by a random hexamer primer. The TaqMan probe and primer (Applied Biosystems, Foster, CA, USA) were used to detect Foxp3. Real-time PCR was performed using an ABI 7700 Sequence Detection System (Applied Biosystems). Each gene expression was normalized to HPRT mRNA copies from the same sample.
Suppressive activity of tumor cells CD4 + T cells were isolated from splenocytes using an isolation kit (Miltenyi Biotech, Gladbach, Germany 
Tumor challenge and survival analysis
Balb/c mice were challenged by subcutaneous injection with 5 Â 10 4 RL#1 viable tumor cells on the left flank (day 0). During follow-up, tumor size was recorded and compared. The primary tumor size was measured twice a week using mechanical calipers, whereas tumor volumes were calculated by the equation, v ¼ pab 2 /6, where a was the longest diameter and b the next longest diameter perpendicular to a. 45, 46 In addition, the life span of each mouse was also recorded individually.
Statistical analysis
All results were expressed as mean±standard error of the mean (s.e.m.) and evaluated by one-way analysis of variance, followed by an unpaired two-tailed Student's t-test for between-group comparison.
